Adaptive Biotechnologies Corp ADPT Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Aug 05, 2022 (filed on Aug 05, 2022)

Insider Name:

Sood Nitin

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-17,540

Price:

$10.98
Jul 08, 2022 (filed on Jul 08, 2022)

Insider Name:

Adams R Mark

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,300

Price:

$10.47
Jul 07, 2022 (filed on Jul 08, 2022)

Insider Name:

Adams R Mark

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-825

Price:

$9.53
Jun 01, 2022 (filed on Jun 03, 2022)

Insider Name:

Peterson Tycho

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

597,157

Price:

--
Jun 01, 2022 (filed on Jun 03, 2022)

Insider Name:

Peterson Tycho

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

374,688

Price:

--
Apr 07, 2022 (filed on Apr 08, 2022)

Insider Name:

Adams R Mark

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-831

Price:

$13.17
Mar 09, 2022 (filed on Mar 09, 2022)

Insider Name:

Robins Chad M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-14,815

Price:

$12.46
Mar 09, 2022 (filed on Mar 09, 2022)

Insider Name:

Robins Chad M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-14,815

Price:

$6.32
Mar 09, 2022 (filed on Mar 09, 2022)

Insider Name:

Robins Chad M

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-14,815

Price:

--
Mar 08, 2022 (filed on Mar 10, 2022)

Insider Name:

Taylor Stacy L

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,387

Price:

$11.44

Filings by filing date

Aug 05, 2022 (filed on Aug 05, 2022)

Insider Name:

Sood Nitin

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-17,540

Price:

$10.98
Jul 08, 2022 (filed on Jul 08, 2022)

Insider Name:

Adams R Mark

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,300

Price:

$10.47
Jul 07, 2022 (filed on Jul 08, 2022)

Insider Name:

Adams R Mark

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-825

Price:

$9.53
Jun 01, 2022 (filed on Jun 03, 2022)

Insider Name:

Peterson Tycho

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

597,157

Price:

--
Jun 01, 2022 (filed on Jun 03, 2022)

Insider Name:

Peterson Tycho

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

374,688

Price:

--
Apr 07, 2022 (filed on Apr 08, 2022)

Insider Name:

Adams R Mark

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-831

Price:

$13.17
Mar 08, 2022 (filed on Mar 10, 2022)

Insider Name:

Taylor Stacy L

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,387

Price:

$11.44
Mar 08, 2022 (filed on Mar 10, 2022)

Insider Name:

Baldo Lance

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,350

Price:

$11.43
Mar 08, 2022 (filed on Mar 10, 2022)

Insider Name:

Lo Francis

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,582

Price:

$11.44
Mar 08, 2022 (filed on Mar 09, 2022)

Insider Name:

Robins Chad M

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-14,815

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	1165 Eastlake Ave E SEATTLE WA 98109
Tel:	1-650-8251656
Website:	https://www.adaptivebiotech.com
IR:	See website

Key People

Chad M. Robins Chairman of the Board, Chief Executive Officer, Co-Founder	Julie Rubinstein President	Harlan S. Robins Co-Founder, Chief Scientific Officer
Tycho Peterson Chief Financial Officer	Mark R. Adams Chief Operating Officer	Francis Lo Chief People Officer
Stacy Taylor Senior Vice President, General Counsel	Sharon Benzeno Chief Commercial Office - Immune Medicine	Nitin Sood Chief Commercial Officer - MRD

Business Overview

Adaptive Biotechnologies Corporation is a commercial-stage company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient's body during and after treatment, known as minimal residual disease (MRD). It uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. It also focuses on developing immune-mediated therapies in oncology and other disease areas.

Financial Overview

For the six months ended 30 June 2022, Adaptive Biotechnologies Corp revenues increased 7% to $82.3M. Net loss increased 28% to $114.8M. Revenues reflect Sequencing revenue increase of 28% to $43.2M. Higher net loss reflects General and administrative - Balancing increase of 46% to $35.9M (expense), Sales and marketing - Balancing value increase of 12% to $42.7M (expense), Stock-based Compensation in increase of 45% to $9.5M (expense).

Employees:	858 as of Dec 31, 2021

Reporting Currency:	U.S. Dollars
Enterprise value:	$1,212M as of Jun 30, 2022
Annual revenue (TTM):	$159.68M as of Jun 30, 2022
EBITDA (TTM):	-$213.26M as of Jun 30, 2022
Net annual income (TTM):	-$232.12M as of Jun 30, 2022
Free cash flow (TTM):	-$241.03M as of Jun 30, 2022
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	142,872,988 as of Jul 29, 2022
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

Adaptive Biotechnologies Corp (OQ:ADPT)